On Tuesday, Honeywell International Inc. (NYSE:HON)’s shares declined -1.45% to $93.89.
Gabelli & Company will host its 21st Annual Aircraft Supplier Conference on September 9 in New York City. This research meeting will feature presentations by senior administration of several leading aerospace and defense companies, with an emphasis on industry dynamics, new technologies, and company fundamentals. Institutional investors should contact their sales representative to register.
Honeywell International Inc. operates as a diversified technology and manufacturing company worldwide. Its Aerospace segment provides aircraft engines, integrated avionics, systems and service solutions, and related products and services for aircraft manufacturers and operators, airlines, military services, and defense and space contractors; and spare parts, and repair and maintenance services for the aftermarket.
Amgen, Inc. (NASDAQ:AMGN)’s shares dropped -1.66% to $145.19.
Amgen (AMGN) declared positive interim results from its open-label extension of the global Phase 2, double-blind, placebo-controlled study evaluating the safety and efficacy of AMG 334 for the prevention of episodic migraine. Patients who entered the open-label phase received AMG 334 70 mg monthly and practiced a sustained reduction in monthly migraine days at week 52.
At one year, patients receiving AMG 334 70 mg practiced an average of a -4.9-day reduction from a baseline of 8.7 mean monthly migraine days, regardless of treatment received during the blinded phase. The 50 percent responder rate (greater than 50 percent reduction in monthly migraine days) was 62 percent at 52 weeks. Additional responder rates were stated for the first time: at 52 weeks the 75 percent responder rate was 38 percent and the 100 percent responder rate was 19 percent.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company’s principal products comprise Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company’s other marketed products comprise Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials.
At the end of Tuesday’s trade, Comcast Corporation (NASDAQ:CMCSK)‘s shares dipped -1.32% to $54.54.
On Wednesday, September 9, 2015, Stephen B. Burke, Chief Executive Officer of NBCUniversal and Senior Executive Vice President of Comcast Corporation ( CMCSK), will take part in the Bank of America Merrill Lynch 2015 Media, Communications & Entertainment Conference in Beverly Hills, CA.
A live webcast of the event will be accessible on the Company’s Investor Relations website at www.cmcsa.com or www.cmcsk.com on Wednesday, September 9, 2015 at 11:45 A.M. Eastern Time. An on-demand replay will be accessible shortly after the conclusion of the presentation.
Comcast Corporation operates as a media and technology company worldwide. It operates through Cable Communications, Cable Netoperates, Broadcast Television, Filmed Entertainment, and Theme Parks segments. The Cable Communications segment offers video, high-speed Internet, and voice services to residential and business customers under the XFINITY brand name. This segment also provides business services, such as cellular backhaul services to mobile network operators; Ethernet network services; and online advertising services.
Centurylink Inc (NYSE:CTL), ended its Tuesday’s trading session with -2.67% loss, and closed at $25.17.
CenturyLink, Inc. (CTL) declared its plans for a multi-city tour featuring industry analysts and select CenturyLink customers and executives to share technology insights and lessons learned with enterprise IT leaders about big data, cloud, security and customer-centric IT.
The Elevate events provide an opportunity for CenturyLink customers, prospects and partners to learn from industry experts about topics important to the disruption taking place in IT recently. The series is co-sponsored by Alcatel Lucent and features CIO Magazine as a media partner.
The series kicks off in Boston on July 15 and continues in key North American and global markets through October 2015. The roundtable forums feature keynotes from leading industry experts, counting CIO Magazine contributing editor Julia King, “Cloudonomics” author Joe Weinman and CenturyLink executives Shirish Lal, David Shacochis, David Mahon and Gary Gauba.
CenturyLink, Inc. provides various communications services to residential, business, governmental, and wholesale customers in the United States. It operates through two segments, Business and Consumer. The company offers broadband services, which allow customers to connect to the Internet through their existing telephone lines or fiber-optic cables; private line services for transmission of large amounts of data between sites; and multi-protocol label switching, a data networking technology to support real-time voice and video.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
